C:\stnweb\Queries\10618288-2.str



Part II – Broader Query



chain nodes :
7 8 9 10 11 12 13 14 16
ring nodes :
1 2 3 4 5 6
chain bonds :
2-7 5-16 7-8 7-9 7-10 10-11 11-12 11-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6 7-8 7-9 7-10 10-11 11-12 11-13
13-14
exact bonds :
5-16
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:Atom 11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:Atom

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 28  PATDPAFULL - New display fields provide for legal status
                  data from INPADOC
 NEWS  4  FEB 28  BABS - Current-awareness alerts (SDIs) available
 NEWS  5  MAR 02  GBFULL: New full-text patent database on STN
 NEWS  6  MAR 03  REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  7  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 22  KOREAPAT now updated monthly; patent information enhanced
 NEWS  9  MAR 22  Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  10 MAR 22  PATDPASPC - New patent database available
 NEWS  11 MAR 22  REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  12 APR 04  EPFULL enhanced with additional patent information and new
                  fields
 NEWS  13 APR 04  EMBASE - Database reloaded and enhanced
 NEWS  14 APR 18  New CAS Information Use Policies available online
 NEWS  15 APR 25  Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
 NEWS  16 APR 28  Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus
 NEWS  17 MAY 23  GBFULL enhanced with patent drawing images
 NEWS  18 MAY 23  REGISTRY has been enhanced with source information from
                  CHEMCATS
 NEWS  19 JUN 06  STN Patent Forums to be held in June 2005
 NEWS  20 JUN 06  The Analysis Edition of STN Express with Discover!
                  (Version 8.0 for Windows) now available
 NEWS  21 JUN 13  RUSSIAPAT: New full-text patent database on STN
 NEWS  22 JUN 13  FRFULL enhanced with patent drawing images
 NEWS  23 JUN 20  MEDICONF to be removed from STN
 NEWS  24 JUN 27  MARPAT displays enhanced with expanded G-group definitions
                  and text labels
 NEWS  25 JUL 01  MEDICONF removed from STN

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:41:49 ON 06 JUL 2005
```

```
=> file reg
COST IN U.S. DOLLARS                                      SINCE FILE      TOTAL
                                                               ENTRY    SESSION
FULL ESTIMATED COST                                             0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:41:56 ON 06 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 JUL 2005  HIGHEST RN 853879-48-8
DICTIONARY FILE UPDATES:   5 JUL 2005  HIGHEST RN 853879-48-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 12:47:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    154 TO ITERATE

100.0% PROCESSED      154 ITERATIONS                              29 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2336 TO     3824
PROJECTED ANSWERS:             257 TO      903

L2           29 SEA SSS SAM L1

=> d ll2 1 5
'LL2' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:
```

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

```
REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid codes are used
SQN    - Protein sequence name information, includes RN

CALC   - Table of calculated properties
EPROP  - Table of experimental properties
PROP   - EPROP and CALC
```

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

```
ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations
```

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

```
HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> d his

     (FILE 'HOME' ENTERED AT 12:41:49 ON 06 JUL 2005)

     FILE 'REGISTRY' ENTERED AT 12:41:56 ON 06 JUL 2005
L1             STRUCTURE UPLOADED
L2          29 S L1
```

=> d l2 1 5 29

L2 ANSWER 1 OF 29 REGISTRY COPYRIGHT 2005 ACS on STN
RN 688307-45-1 REGISTRY
ED Entered STN: 01 Jun 2004
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H22 F3 N3 O6 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 5 OF 29 REGISTRY COPYRIGHT 2005 ACS on STN
RN 622395-09-9 REGISTRY
ED Entered STN: 01 Dec 2003
CN 1,4-Piperidinedicarboxamide, 4-[[4-(4-butoxyphenyl)-1-piperazinyl]sulfonyl]-N4-hydroxy-N1,N1-bis(1-methylethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H45 N5 O6 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 29 OF 29 REGISTRY COPYRIGHT 2005 ACS on STN
RN 210915-73-4 REGISTRY
ED Entered STN: 06 Sep 1998
CN 2-Piperidinecarboxamide, 1-[[4-(4-chloro-2-methylphenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C17 H25 Cl N4 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 12:41:49 ON 06 JUL 2005)

FILE 'REGISTRY' ENTERED AT 12:41:56 ON 06 JUL 2005
L1 STRUCTURE UPLOADED
L2 29 S L1

=> s l1 sss full
FULL SEARCH INITIATED 12:48:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3033 TO ITERATE

100.0% PROCESSED 3033 ITERATIONS 500 ANSWERS
SEARCH TIME: 00.00.01

L3 500 SEA SSS FUL L1

=> save l3
ENTER NAME OR (END):ten618288/a
ANSWER SET L3 HAS BEEN SAVED AS 'TEN618288/A'

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 171.58 171.79

FILE 'CAPLUS' ENTERED AT 12:49:13 ON 06 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Jul 2005 VOL 143 ISS 2
FILE LAST UPDATED: 5 Jul 2005 (20050705/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 7 L3

=> d l4 1-7 bib abs fhitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
Full Text
AN 2005:409509 CAPLUS
DN 142:463765
TI Preparation of piperidinyl- and piperazinylsulfonylmethyl hydroxamic acids and their use as protease inhibitors
IN Brown, David L.; Grapperhaus, Margaret L.; Kassab, Darren J.; Massa, Mark A.; Mcdonald, Joseph J.; Mullins, Patrick B.; Rico, Joseph G.; Schmidt, Michelle A.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 644 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042521	A2	20050512	WO 2004-US36666	20041103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-700202 A 20031103
GI



I

AB Title compds. I [A1-2 = H, alkyl, alkoxyalkyl, etc.; Rx = halo, CN, OH, NO2, etc.; E2 = CO, COO, OCO, amino, etc.; E3 = alkyl, alkenyl, alkynyl, etc.] are prepd. For instance, 4-[[4-(5-butylpyrazin-2-yl)piperazin-1-

yl]sulfonyl]-N-(hydroxy)tetrahydro-2H-pyran-4-carboxamide•2HCl (II) is prepd. in 8 steps from 1-(tert-butoxycarbonyl)piperazine, 2-chloropyrazine, butylmagnesium chloride, bis(2-bromoethyl)ether and O-(tetrahydro-2H-pyran-2-yl)hydroxyamine. II exhibits Ki = >10,000 nM for MMP-1, 1.52 nM for MMP-2, 0.696 nM for MMP-9, 1.82 nM for MMP-13 and 4290 nM for MMP-14. I are useful for the treatment of conditions assocd. with MMP activity and/or aggrecanase activity.

IT **622386-20-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)

RN 622386-20-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[4-(2,2,2-trifluoroethoxy)phenyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

Full Text

AN 2004:718284 CAPLUS

DN 141:236618

TI Inhibitors of hepatitis C virus, compositions and treatments using the same

IN Duggal, Rohit; Patick, Amy Karen; Zhao, Weidong; Herlihy, Koleen Jill; Sha, Eiann; Liu, Wei

PA Pfizer Inc., USA

SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073599	A2	20040902	WO 2004-IB403	20040206
WO 2004073599	A3	20041223		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,

GQ, GW, ML, MR, NE, SN, TD, TG

	US 2004229817	A1	20041118	US 2004-782679	20040218
PRAI	US 2003-448253P	P	20030218		

OS MARPAT 141:236618

AB The invention relates to methods of inhibiting HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amt. of a hydroxamate MMP inhibitor, and compn. comprising the same.

IT **210915-19-8**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors of hepatitis C virus)

RN 210915-19-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN Apps

Full Text

AN 2003:875282 CAPLUS

DN 139:364961

TI Preparation of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Brown, David L.; Carroll, Jeffery N.; Chen, Yiyuan; Fobian, Yvette; Freskos, John N.; Gasiecki, Alan F.; Grapperhaus, Margaret; Heintz, Robert M.; Hockerman, Susan L.; Kassab, Darren J.; Khanna, Ish Kumar; Kolodziej, Stephen A.; Massa, Mark; Mcdonald, Joseph; Mischke, Brent V.; Mischke, Deborah A.; Mullins, Patrick B.; Nagy, Mark; Norton, Monica B.; Rico, Joseph G.; Schmidt, Michelle A.; Stehle, Nathan W.; Talley, John J.; Vernier, William F.; Villamill, Clara I.; Wang, Lijuan Jane; Wynn, Thomas A.

PA Pharmacia Corporation, USA; et al.

SO PCT Int. Appl., 819 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091247	A2	20031106	WO 2003-US13123	20030425
	WO 2003091247	A3	20040115		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2483314	AA	20031106	CA 2003-2483314	20030425
	US 2005009838	A1	20050113	US 2003-618288	20030425
	EP 1501827	A2	20050202	EP 2003-718529	20030425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009671	A	20050503	BR 2003-9671	20030425
PRAI	US 2002-375598P	P	20020425		
	US 2002-380713P	P	20020515		
	US 2002-392021P	P	20020627		
	WO 2003-US13123	W	20030425		

OS MARPAT 139:364961

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A1 and A2 together with the C to which they are bonded join to form (un)substituted-heterocyclyl or -carbocyclyl, or A1 and A2 are independently selected from H, alkyl, alkoxyalkyl, alkenyl, alkynyl, etc.; Rx = H, halo, CN, OH, NO2, alkyl, alkenyl, alkoxy, alkoxyalkyl, heterocyclyl, etc.; Y = N, CH, or CRx; E1 = (un)substituted heteroaryl; E2 = O, CO, C(O)O, OC(O), bond, S, etc.; E3 = halo, CN, (un)substituted-alkyl, -alkenyl, -alkynyl, -heterocyclyl, heterocyclylalkyl, etc.] and their pharmaceutically acceptable salts are prepd. and disclosed as protease inhibitors. Thus, e.g., II·HCl was prepd. with piperazine ring formation occurring via cyclization of 2,2,2-trifluoroethoxyaniline (prepn. given) with N,N-di(2-chloroethyl)methylsulfonamide (prepn. given) to provide piperazinyl intermediate III which was converted in five addnl. steps to the desired product. This invention is directed generally to proteinase (also known as 'protease') inhibitors, and more particularly, inhibitors of matrix metalloproteinase (also known as 'matrix metalloprotease' or 'MMP') activity and/or aggrecanase activity. In assays to det. inhibition consts. (Ki) against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14, I possessed values ranging from 0.13->10,000. This invention also is directed to compns. of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathol. conditions) assocd. with MMP activity and/or aggrecanase activity.

IT **622394-08-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compds.; prepn. of piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as matrix metalloproteinase inhibitors)

RN 622394-08-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(2,2,2-trifluoroethoxy)methyl]phenyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
Full Text
AN 2002:312012 CAPLUS
DN 136:340996
TI Preparation of sulfamides as metalloprotease inhibitors
IN Broka, Chris Allen; Campbell, Jeffrey Allen; Castelhano, Arlindo Lucas; Chen, Jian Jeffrey; Hendricks, Robert Than; Melnick, Michael Joseph; Walker, Keith Adrian Murray
PA Syntex (U.S.A.) LLC, USA; Agouron Pharmaceuticals, Inc.
SO U.S., 47 pp., Cont.-in-part of U.S. 6,143,744.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6376506	B1	20020423	US 1999-469677	19991222
	CA 2278694	AA	19980730	CA 1998-2278694	19980114
	AU 9866140	A1	19980818	AU 1998-66140	19980114
	AU 730127	B2	20010222		
	EP 958287	A1	19991124	EP 1998-907943	19980114
	EP 958287	B1	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9807508	A	20000321	BR 1998-7508	19980114
	NZ 336625	A	20010427	NZ 1998-336625	19980114
	JP 2001523222	T2	20011120	JP 1998-531537	19980114
	JP 3563411	B2	20040908		
	AT 223909	E	20020915	AT 1998-907943	19980114
	ZA 9800376	A	19980723	ZA 1998-376	19980116
	US 5998412	A	19991207	US 1998-9951	19980121
	NO 9903587	A	19990922	NO 1999-3587	19990722
	NO 313635	B1	20021104		
	MX 9906822	A	20000131	MX 1999-6822	19990722
	US 6130220	A	20001010	US 1999-369677	19990805
	US 6143744	A	20001107	US 1999-369501	19990805
PRAI	US 1997-36714P	P	19970123		
	US 1997-62209P	P	19971016		
	US 1998-9951	A3	19980121		
	US 1999-369501	A2	19990805		
	WO 1998-EP180	W	19980114		

OS MARPAT 136:340996
AB Sulfamides RCOCR1R2NR3SO2NR4R5 [R = OH, NHOH or N/O-alkyl or -aryl derivs.; R1, R2, R3 = H, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, (hetero)aryl, acylalkyl, etc.; R1R2C may be a (hetero)carbocycle or R3 together with R1 or R2 form a heterocycloamino group; R4, R5 = H, alkyl, heteroalkyl, cycloalkyl, cycloalkylalkyl, aryl, (hetero)aralkyl or -aralkenyl; R4R5N may be a heterocycloamino group or R4 or R5 together with R3 forms an alkylene group (with provisos)], as individual isomers or mixts. of isomers, or their pharmaceutically-acceptable salts or prodrugs were prepd. as inhibitors of metalloproteases. Thus, 2-(R)-[(1,2,3,4-tetrahydro-β-carbolino-2-sulfonyl)amino]propionic acid (claimed compd.) was prepd. by treating D-alanine Me ester hydrochloride with chlorosulfonyl isocyanate/2-chloroethanol, reaction of the oxazolidone formed with 1,2,3,4-tetrahydro-β-carboline, and sapon. Metalloprotease and TNF-α inhibitory test data are tabulated.
IT **210915-19-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of sulfamides as metalloprotease inhibitors)
RN 210915-19-8 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
Full Text
AN 2000:553575 CAPLUS
DN 133:164006
TI Preparation of sulfamato hydroxamic acid metalloprotease inhibitors
IN De Crescenzo, Gary A.; Rico, Joseph G.; Boehm, Terri L.; Carroll, Jeffery N.; Kassab, Darren J.; Mischke, Deborah A.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 628 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000046221	A1	20000810	WO 2000-US3061	20000207
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2362230	AA	20000810	CA 2000-2362230	20000207
	EP 1157021	A1	20011128	EP 2000-905996	20000207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008440	A	20020326	BR 2000-8440	20000207
	US 6448250	B1	20020910	US 2000-499276	20000207
	JP 2002536373	T2	20021029	JP 2000-597291	20000207
	EE 200100410	A	20021216	EE 2001-410	20000207
	AU 775701	B2	20040812	AU 2000-27574	20000207
	US 6372758	B1	20020416	US 2001-884548	20010619
	NO 2001003850	A	20010919	NO 2001-3850	20010807
	BG 105788	A	20020228	BG 2001-105788	20010807
	ZA 2001006492	A	20030507	ZA 2001-6492	20010807
	US 6492367	B1	20021210	US 2002-84713	20020226
	US 6800646	B1	20041005	US 2002-262622	20020930
	US 2005049280	A1	20050303	US 2004-887450	20040708
PRAI	US 1999-119181P	P	19990208		
	US 2000-499276	A1	20000207		

	WO 2000-US3061	W	20000207
	US 2002-84713	A3	20020226
	US 2002-262622	A3	20020930

OS MARPAT 133:164006

GI



II

AB The title compds. R20C(O)CR1R2SO2NR3aR3b (I) [wherein R1 and R2 taken together with the C to which they are attached = (un)substituted heterocyclyl or cycloalkyl; or R1 and R2 = independently H, (un)substituted (cyclo)alkyl, alkyloxylalkyl, alkylthioalkyl, alkenyl, alkynyl, aryl(alkyl), heterocyclyl(alkyl), etc.; R3a and R3b = independently H or (un)substituted alkyl, alkenyl, alkynyl, (hetero)aryl, heterocyclyl, cycloalkyl, or alkoxyalkyl; R20 = OH, alkoxyl, aryloxy, NH-OR22, or NH-OR14; R22 = selectively removable protecting group, such as 2-THP, benzyl, trisubstituted silyl, o-NO2C6H4, etc.; R14 = H, a cation, or acyl] were prepd. as selective matrix metalloproteinase (MMP) inhibitors for the treatment of various conditions, such as pathol. breakdown of connective tissue, osteoarthritis, inflammation, tumor growth, and angiogenesis. Examples include the syntheses of over 50 piperidinylsulfonyl and piperazinylsulfonyl hydroxamic acids and their intermediates. In vitro MMP assay data for I show selective inhibition of MMP-2 and MMP-13 compared to MMP-1. Some inhibition assay data for MMP-3, MMP-7, MMP-8, MMP-9, and MMP-14 are also given. Thus, II was prepd. in a multi-step sequence involving addn. of MeOC(O)Cl to 1-(methylsulfonyl)-4-(benzyloxy)piperidine (4-step prepn. given) to form the methylene sulfonamide, cycloaddn. of dibromodiethyl ether to give the THF-substituted sulfonamide, deesterification, addn. of O-(tetrahydro-2H-pyran-2-yl)hydroxylamine to form the THP hydroxamate, and deprotection to yield the desired hydroxamic acid. II inhibited MMP-1, MMP-2, and MMP-13 with IC50 values of < 10,000 nM, 7.0 nM and 20.0 nM, resp.

IT **287952-49-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of sulfamato hydroxamic acid metalloprotease inhibitors by cycloaddn. of dihalodialkyl ethers and amines to methylene sulfonamides followed by addn. of hydroxylamines)

RN 287952-49-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[4-(trifluoromethoxy)phenyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
Full Text
AN 2000:84604 CAPLUS
DN 132:141951
TI Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
IN Bocan, Thomas Michael Andrew
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000004892	A2	20000203	WO 1999-US13948	19990618
	WO 2000004892	A3	20000518		
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2335062	AA	20000203	CA 1999-2335062	19990618
	AU 9947017	A1	20000214	AU 1999-47017	19990618
	BR 9912296	A	20010417	BR 1999-12296	19990618
	EP 1098662	A2	20010516	EP 1999-930483	19990618
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100205	T2	20010521	TR 2001-200100205	19990618
	EE 200100046	A	20020617	EE 2001-46	19990618
	JP 2002521328	T2	20020716	JP 2000-560885	19990618
	ZA 2001000294	A	20020110	ZA 2001-294	20010110
	BG 105162	A	20011231	BG 2001-105162	20010117
	NO 2001000291	A	20010118	NO 2001-291	20010118
	HR 2001000055	A1	20020430	HR 2001-55	20010119
PRAI	US 1998-93639P	P	19980721		
	WO 1999-US13948	W	19990618		

AB Acyl-CoA:cholesterol acyltransferase (ACAT) and matrix metalloproteinase (MMP) inhibitors are coadministered for the redn. of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal. The direct antiatherosclerotic potential of the combination of ACAT inhibitor, [[2,4,6-tris-(1-

methyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl sulfamic acid, and the HMG-CoA reductase inhibitor, simavastatin, in rabbits was studied. A tablet contained 2-(4'-bromobiphenyl-4-sulfonylamino)-3-Me butyric acid 25 ACAT compd. lactose 50, corn starch 20, and magnesium stearate 5 mg.

IT **210915-19-8**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. contg. ACAT and MMP inhibitors for treatment of atherosclerotic lesions)

RN 210915-19-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

Full Text

AN 1998:498326 CAPLUS

DN 129:148991

TI Preparation of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors

IN Broka, Chris Allen; Campbell, Jeffrey Allen; Castelhano, Arlindo Lucas; Chen, Jian Jeffrey; Hendricks, Robert Than; Melnick, Michael Joseph; Walker, Keith Adrian Murray

PA F. Hoffmann-La Roche A.-G., Switz.; Agouron Pharmaceuticals, Inc.

SO Ger. Offen., 84 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19802350	A1	19980730	DE 1998-19802350	19980122
CA 2278694	AA	19980730	CA 1998-2278694	19980114
WO 9832748	A1	19980730	WO 1998-EP180	19980114
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9866140	A1	19980818	AU 1998-66140	19980114
AU 730127	B2	20010222		
EP 958287	A1	19991124	EP 1998-907943	19980114
EP 958287	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9807508	A	20000321	BR 1998-7508	19980114
NZ 336625	A	20010427	NZ 1998-336625	19980114

	JP 2001523222	T2	20011120	JP 1998-531537	19980114
	JP 3563411	B2	20040908		
	AT 223909	E	20020915	AT 1998-907943	19980114
	CN 1093125	B	20021023	CN 1998-803233	19980114
	PT 958287	T	20021231	PT 1998-907943	19980114
	ES 2183331	T3	20030316	ES 1998-907943	19980114
	ZA 9800376	A	19980723	ZA 1998-376	19980116
	IT 1298163	B1	19991220	IT 1998-MI91	19980120
	FR 2758559	A1	19980724	FR 1998-601	19980121
	GB 2321641	A1	19980805	GB 1998-1393	19980122
	GB 2321641	B2	20010401		
	ES 2136037	A1	19991101	ES 1998-113	19980122
	ES 2136037	B1	20001116		
	NO 9903587	A	19990922	NO 1999-3587	19990722
	NO 313635	B1	20021104		
	MX 9906822	A	20000131	MX 1999-6822	19990722
PRAI	US 1997-36714P	P	19970123		
	US 1997-62209P	P	19971016		
	WO 1998-EP180	W	19980114		

OS MARPAT 129:148991

GI



II

AB R10COCR1R2NR3SO2NR20R21 [I; R1-R3 = H, (CO-interrupted) alkyl, heterocyclyl(alkyl), (hetero)aryl(alkyl), etc.; R1R2, R1R3, R2R3 = atoms to complete a ring; R10 = NR11OR12; R11,R12 = H or (ar)alkyl; R20,R21 = H, alkyl, (hetero)aryl[alk(en)yl], etc.; NR20R21heterocyclyl] were prepd. Thus, (R)-1-[4-(4-chlorobenzoyl)piperidine-1-sulfonyl]piperidine-2-carboxylic acid was amidated by H2NOCMe3 and the product deprotected to give title compd. (R)-II. Data for biol. activity of I were given.

IT **210915-19-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors)

RN 210915-19-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 12:41:49 ON 06 JUL 2005)

     FILE 'REGISTRY' ENTERED AT 12:41:56 ON 06 JUL 2005
L1              STRUCTURE UPLOADED
L2           29 S L1
L3          500 S L1 SSS FULL
                SAVE L3 TEN618288/A

     FILE 'CAPLUS' ENTERED AT 12:49:13 ON 06 JUL 2005
L4            7 S L3

=> d l4 2 4-7 bib hitstr

L4   ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2005 ACS on STN
Full Text
AN   2004:718284  CAPLUS
DN   141:236618
TI   Inhibitors of hepatitis C virus, compositions and treatments using the
     same
IN   Duggal, Rohit; Patick, Amy Karen; Zhao, Weidong; Herlihy, Koleen Jill;
     Sha, Eiann; Liu, Wei
PA   Pfizer Inc., USA
SO   PCT Int. Appl., 48 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2004073599        A2    20040902    WO 2004-IB403           20040206
     WO 2004073599        A3    20041223
         W:  AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,
             BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,
             CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,
             ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,
             IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,
             LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,
             MZ, MZ, NA, NI
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004229817        A1    20041118    US 2004-782679          20040218
PRAI US 2003-448253P      P     20030218
OS   MARPAT 141:236618
IT 210915-19-8 256646-40-9
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (inhibitors of hepatitis C virus)
RN   210915-19-8  CAPLUS
CN   2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-
     hydroxy- (9CI)  (CA INDEX NAME)
```



RN 256646-40-9 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
Full Text
AN 2002:312012 CAPLUS
DN 136:340996
TI Preparation of sulfamides as metalloprotease inhibitors
IN Broka, Chris Allen; Campbell, Jeffrey Allen; Castelhano, Arlindo Lucas; Chen, Jian Jeffrey; Hendricks, Robert Than; Melnick, Michael Joseph; Walker, Keith Adrian Murray
PA Syntex (U.S.A.) LLC, USA; Agouron Pharmaceuticals, Inc.
SO U.S., 47 pp., Cont.-in-part of U.S. 6,143,744.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6376506	B1	20020423	US 1999-469677	19991222
	CA 2278694	AA	19980730	CA 1998-2278694	19980114
	AU 9866140	A1	19980818	AU 1998-66140	19980114
	AU 730127	B2	20010222		
	EP 958287	A1	19991124	EP 1998-907943	19980114
	EP 958287	B1	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9807508	A	20000321	BR 1998-7508	19980114
	NZ 336625	A	20010427	NZ 1998-336625	19980114
	JP 2001523222	T2	20011120	JP 1998-531537	19980114
	JP 3563411	B2	20040908		
	AT 223909	E	20020915	AT 1998-907943	19980114
	ZA 9800376	A	19980723	ZA 1998-376	19980116
	US 5998412	A	19991207	US 1998-9951	19980121
	NO 9903587	A	19990922	NO 1999-3587	19990722
	NO 313635	B1	20021104		
	MX 9906822	A	20000131	MX 1999-6822	19990722
	US 6130220	A	20001010	US 1999-369677	19990805
	US 6143744	A	20001107	US 1999-369501	19990805
PRAI	US 1997-36714P	P	19970123		
	US 1997-62209P	P	19971016		

US 1998-9951 A3 19980121
US 1999-369501 A2 19990805
WO 1998-EP180 W 19980114
OS MARPAT 136:340996
IT **210915-19-8P 210915-20-1P 210915-32-5P**
210915-73-4P 210915-75-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfamides as metalloprotease inhibitors)
RN 210915-19-8 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 210915-20-1 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210915-32-5 CAPLUS
CN 3-Isoquinolinecarboxamide, 2-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-1,2,3,4-tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 210915-73-4 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-chloro-2-methylphenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 210915-75-6 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(2,3-dimethylphenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



IT **210917-40-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of sulfamides as metalloprotease inhibitors)
RN 210917-40-1 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-[[(1,1-dimethylethyl)dimethylsilyl]oxy]- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
Full Text
AN 2000:553575 CAPLUS
DN 133:164006
TI Preparation of sulfamato hydroxamic acid metalloprotease inhibitors
IN De Crescenzo, Gary A.; Rico, Joseph G.; Boehm, Terri L.; Carroll, Jeffery N.; Kassab, Darren J.; Mischke, Deborah A.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 628 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000046221	A1	20000810	WO 2000-US3061	20000207
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2362230	AA	20000810	CA 2000-2362230	20000207
	EP 1157021	A1	20011128	EP 2000-905996	20000207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008440	A	20020326	BR 2000-8440	20000207
	US 6448250	B1	20020910	US 2000-499276	20000207
	JP 2002536373	T2	20021029	JP 2000-597291	20000207
	EE 200100410	A	20021216	EE 2001-410	20000207
	AU 775701	B2	20040812	AU 2000-27574	20000207
	US 6372758	B1	20020416	US 2001-884548	20010619
	NO 2001003850	A	20010919	NO 2001-3850	20010807
	BG 105788	A	20020228	BG 2001-105788	20010807
	ZA 2001006492	A	20030507	ZA 2001-6492	20010807
	US 6492367	B1	20021210	US 2002-84713	20020226
	US 6800646	B1	20041005	US 2002-262622	20020930
	US 2005049280	A1	20050303	US 2004-887450	20040708
PRAI	US 1999-119181P	P	19990208		
	US 2000-499276	A1	20000207		
	WO 2000-US3061	W	20000207		
	US 2002-84713	A3	20020226		
	US 2002-262622	A3	20020930		

OS MARPAT 133:164006
IT **287952-49-2P 287953-34-8P 287953-37-1P**
287953-69-9P 287954-82-9P 287954-97-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; prepn. of sulfamato hydroxamic acid metalloprotease inhibitors by cycloaddn. of dihalodialkyl ethers and amines to methylene sulfonamides followed by addn. of hydroxylamines)

RN 287952-49-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[[4-[4-(trifluoromethoxy)phenyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 287953-34-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[[4-(4-pentylphenyl)-1-piperazinyl]sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 287953-37-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-4-[(4-phenyl-1-piperazinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 287953-69-9 CAPLUS
CN 4-Piperidinecarboxamide, 4-[[4-(4-butoxyphenyl)-1-piperazinyl]sulfonyl]-1-(2-methoxyethyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 287954-82-9 CAPLUS
CN 4-Piperidinecarboxamide, 1-(phenylmethyl)-4-[(4-phenyl-1-piperazinyl)sulfonyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 287954-97-6 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-(4-butoxy-3-methylphenyl)-1-piperazinyl]sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



IT **287952-00-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compd.; prepn. of sulfamato hydroxamic acid metalloprotease inhibitors by cycloaddn. of dihalodialkyl ethers and amines to methylene sulfonamides followed by addn. of hydroxylamines)
RN 287952-00-5 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-1-(phenylmethyl)-4-[(4-phenyl-1-piperazinyl)sulfonyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 287951-99-9
CMF C23 H30 N4 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **287951-57-9P 287951-78-4P 287951-79-5P 287951-83-1P 287951-84-2P 287952-01-6P 287952-02-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of sulfamato hydroxamic acid metalloprotease

inhibitors by cycloaddn. of dihalodialkyl ethers and amines to methylene sulfonamides followed by addn. of hydroxylamines)

RN 287951-57-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenyl]-1-piperazinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 287951-78-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(4-pentylphenyl)-1-piperazinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 287951-79-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[(4-phenyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 287951-83-1 CAPLUS

CN 4-Piperidinecarboxamide, 4-[[4-[4-(1,1-dimethylethyl)phenyl]-1-piperazinyl]sulfonyl]-N-hydroxy-1-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 287951-84-2 CAPLUS
CN 4-Piperidinecarboxamide, 4-[[4-(4-butoxyphenyl)-1-piperazinyl]sulfonyl]-N-hydroxy-1-(2-methoxyethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 287952-01-6 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-1-(phenylmethyl)-4-[(4-phenyl-1-piperazinyl)sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 287952-02-7 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-(4-butoxy-3-methylphenyl)-1-piperazinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
Full Text
AN 2000:84604 CAPLUS
DN 132:141951
TI Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
IN Bocan, Thomas Michael Andrew
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000004892	A2	20000203	WO 1999-US13948	19990618
	WO 2000004892	A3	20000518		
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2335062	AA	20000203	CA 1999-2335062	19990618
	AU 9947017	A1	20000214	AU 1999-47017	19990618
	BR 9912296	A	20010417	BR 1999-12296	19990618
	EP 1098662	A2	20010516	EP 1999-930483	19990618
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100205	T2	20010521	TR 2001-200100205	19990618
	EE 200100046	A	20020617	EE 2001-46	19990618
	JP 2002521328	T2	20020716	JP 2000-560885	19990618
	ZA 2001000294	A	20020110	ZA 2001-294	20010110
	BG 105162	A	20011231	BG 2001-105162	20010117
	NO 2001000291	A	20010118	NO 2001-291	20010118
	HR 2001000055	A1	20020430	HR 2001-55	20010119
PRAI	US 1998-93639P	P	19980721		
	WO 1999-US13948	W	19990618		

IT **210915-19-8 256646-40-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. ACAT and MMP inhibitors for treatment of atherosclerotic lesions)
RN 210915-19-8 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 256646-40-9 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
Full Text
AN 1998:498326 CAPLUS
DN 129:148991
TI Preparation of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors
IN Broka, Chris Allen; Campbell, Jeffrey Allen; Castelhano, Arlindo Lucas; Chen, Jian Jeffrey; Hendricks, Robert Than; Melnick, Michael Joseph; Walker, Keith Adrian Murray
PA F. Hoffmann-La Roche A.-G., Switz.; Agouron Pharmaceuticals, Inc.
SO Ger. Offen., 84 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19802350	A1	19980730	DE 1998-19802350	19980122
CA 2278694	AA	19980730	CA 1998-2278694	19980114
WO 9832748	A1	19980730	WO 1998-EP180	19980114
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9866140	A1	19980818	AU 1998-66140	19980114
AU 730127	B2	20010222		
EP 958287	A1	19991124	EP 1998-907943	19980114
EP 958287	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9807508	A	20000321	BR 1998-7508	19980114
NZ 336625	A	20010427	NZ 1998-336625	19980114
JP 2001523222	T2	20011120	JP 1998-531537	19980114
JP 3563411	B2	20040908		
AT 223909	E	20020915	AT 1998-907943	19980114
CN 1093125	B	20021023	CN 1998-803233	19980114
PT 958287	T	20021231	PT 1998-907943	19980114
ES 2183331	T3	20030316	ES 1998-907943	19980114
ZA 9800376	A	19980723	ZA 1998-376	19980116
IT 1298163	B1	19991220	IT 1998-MI91	19980120
FR 2758559	A1	19980724	FR 1998-601	19980121
GB 2321641	A1	19980805	GB 1998-1393	19980122

	GB 2321641	B2	20010401		
	ES 2136037	A1	19991101	ES 1998-113	19980122
	ES 2136037	B1	20001116		
	NO 9903587	A	19990922	NO 1999-3587	19990722
	NO 313635	B1	20021104		
	MX 9906822	A	20000131	MX 1999-6822	19990722
PRAI	US 1997-36714P	P	19970123		
	US 1997-62209P	P	19971016		
	WO 1998-EP180	W	19980114		

OS MARPAT 129:148991

IT **210915-19-8P 210915-20-1P 210915-32-5P**
210915-73-4P 210915-75-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors)

RN 210915-19-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 210915-20-1 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]-N-hydroxy-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210915-32-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-1,2,3,4-tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 210915-73-4 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-chloro-2-methylphenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 210915-75-6 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(2,3-dimethylphenyl)-1-piperazinyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



IT **210917-40-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors)

RN 210917-40-1 CAPLUS
CN 2-Piperidinecarboxamide, 1-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]-N-[[(1,1-dimethylethyl)dimethylsilyl]oxy]- (9CI) (CA INDEX NAME)



```
=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    54.68     226.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.11      -5.11

FILE 'CAOLD' ENTERED AT 12:53:36 ON 06 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> s l3
L5            0 L3

=>
```